HUNT FOR 10-PLEX BIOMARKERS WITH UNMATCHED SENSITIVITY


With Quanterix SP-X, unparalleled Simoa™10-plex detection of circulating protein biomarkers is now possible at the earliest stages of disease progression – even at healthy baseline levels.


Introducing the Quanterix SP-X Imaging and Analysis System,


detection at both acute and baseline levels. With the new SP-X, oncology and immuno-oncology researchers and others who rely on robust multiplexing capabilities now have access to next generation Simoa planar technology in an easy-to-use


research, and ultimately accelerate drug approvals. ™


Visit quanterix.com/SP-X for more information.


Quanterix.com | © 2018 Quanterix, Inc. SP-X™ is a registered trademark of Quanterix, Inc. For research use only. Not for diagnostic procedures.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68